lg-100567 and Uterine-Cervical-Neoplasms

lg-100567 has been researched along with Uterine-Cervical-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for lg-100567 and Uterine-Cervical-Neoplasms

Article	Year
Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. Journal of medicinal chemistry, 1996, Jul-05, Volume: 39, Issue:14 Retinoic acid receptor (RAR) active retinoids have proven therapeutically useful for treating certain cancers and dermatological diseases. Herein, we describe the discovery of two new RAR active trienoic acid retinoids, (2E,4E,6E)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2, 4,6-trienoic acid (10a, ALRT1550) and (2E,4E,6Z)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2, 4,6-trienoic acid (10b, LG100567). ALRT1550 is a RAR selective retinoid which exhibits exceptional potency in both competitive binding and cotransfection assays. Moreover, it is the most potent antiproliferative retinoid described to date and thus has implications for the treatment of certain cancers. LG100567 is a potent panagonist which activates both RARs and retinoid X receptors. Topics: Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Thymidine; Transcription Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms	1996

Article

Year

Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.

Journal of medicinal chemistry, 1996, Jul-05, Volume: 39, Issue:14

Retinoic acid receptor (RAR) active retinoids have proven therapeutically useful for treating certain cancers and dermatological diseases. Herein, we describe the discovery of two new RAR active trienoic acid retinoids, (2E,4E,6E)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2, 4,6-trienoic acid (10a, ALRT1550) and (2E,4E,6Z)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2, 4,6-trienoic acid (10b, LG100567). ALRT1550 is a RAR selective retinoid which exhibits exceptional potency in both competitive binding and cotransfection assays. Moreover, it is the most potent antiproliferative retinoid described to date and thus has implications for the treatment of certain cancers. LG100567 is a potent panagonist which activates both RARs and retinoid X receptors.

Topics: Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Thymidine; Transcription Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms

1996